SM
CDTX

Sabby Management’s Cidara Therapeutics CDTX Stock Holding History

Sabby Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,215
Closed -$521K – 163
2017
Q3 		$521K Sell
3,215
-3,035
-49% -$432K 0.03% 99
2017
Q2 		$938K Sell
6,250
-2,630
-30% -$364K 0.06% 107
2017
Q1 		$1.39M Sell
8,880
-5,740
-39% -$1.01M 0.07% 113
2016
Q4 		$3.04M Buy
14,620
+5,102
+54% +$1.06M 0.18% 76
2016
Q3 		$2.18M Buy
9,518
+8,504
+839% +$1.97M 0.08% 122
2016
Q2 		$209K Sell
1,014
-1,000
-50% -$242K 0.01% 246
2016
Q1 		$512K Buy
+2,014
New +$464K 0.03% 211
2015
Q4 		– Sell
-15,302
Closed -$3.89M – 331
2015
Q3 		$3.89M Buy
15,302
+553
+4% +$158K 0.16% 101
2015
Q2 		$4.14M Buy
+14,749
New +$4.54M 0.15% 107

Other funds holding CDTX

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management's CDTX Position: Q4 2017 in Review

Sabby Management sold out of Cidara Therapeutics (CDTX) in Q4 2017, closing a stake of 3,215 shares — an estimated $521K sold.

Sabby Management first reported a position in CDTX in Q2 2015 and held it in 9 quarters. The position peaked at $4.14M in Q2 2015. 48 funds tracked by Wall St. Rank hold CDTX as of Q4 2017.

  • Sabby Management reported no remaining Cidara Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Sabby Management sold 3,215 Cidara Therapeutics shares in Q4 2017, an estimated $521K.
  • Sabby Management first reported a position in Cidara Therapeutics in Q2 2015 and held it in 9 quarters.
  • Sabby Management's Cidara Therapeutics position peaked at $4.14M in Q2 2015.
  • 48 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2017.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.